Avid Bioservices Inc (CDMO)

[biopharm]

Avid BOD have not updated shareholders yet on any communications with their decision to allow Oncologie to advance PS Trgetinh IP / Biomarkers etc and now with ongoing FBI investigation regarding IP related to cancer researchers...updates should be coming

Flipped PS travels the bloodstream and breaks the blood brain barrier ....looks like Independent BOD Catherine Mackey will be confronted with questions

__________________

Regulating the interaction between tam ligands and lipid membranes with exposed phosphatidylserine

Inventor
Greg E. Lemke
Lawrence C. Fritz
Benedikt Vollrath
Carla V. Rothlin

https://patents.google.com/patent/WO2014018535A1/ar

___________________

Lipid membranes with exposed phosphatidylserine as tam ligands, use for treating autoimmune diseases

Inventor
Greg E. Lemke
Lawrence C. Fritz
Benedikt Vollrath
Carla V. Rothlin

Current Assignee Salk Institute for Biological Studies
Celldex Therapeutics Inc

https://patents.google.com/patent/EP3184121A2/en

_____________________

Patents Assigned to AMPRION, INC.
DETECTION OF MISFOLDED TAU PROTEIN
Publication number: 20180335438
Abstract: Methods and kits are provided for amplifying and detecting misfolded tau protein from samples, for example, from patients having tauopathies such as Alzheimer's Disease, Progressive Supranuclear Palsy, and the like.

Type: Application
Filed: May 16, 2018
Publication date: November 22, 2018
Applicants: Amprion, Inc., BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM
Inventors: Claudio Soto-Jara, Russell M. Lebovitz, Benedikt K. Vollrath, Mohammad Shahnawaz, Nicolas Mendez Dinamarca
DETECTION OF MISFOLDED PROTEINS
Publication number: 20180196069
Abstract: Methods and kits are provided for amplifying and detecting misfolded proteins from samples, for example, from patients having Alzheimer's Disease, Parkinson's Disease, and the like. For example, a method for determining a presence of soluble, misfolded protein in a sample may include contacting the sample with a monomeric, folded protein to form an incubation mixture; conducting an incubation cycle two or more times effective to form an amplified portion of misfolded protein; incubating the incubation mixture effective to cause misfolding and/or aggregation of at least a portion of the monomeric, folded protein; physically disrupting the incubation mixture effective to break up at least a portion of any protein aggregate present; and determining the presence of the soluble, misfolded protein in the sample by detecting at least a portion of the soluble, misfolded protein. The monomeric, folded protein and the soluble, misfolded protein may exclude prion protein (PrP) and isoforms thereof.

Type: Application
Filed: March 8, 2018
Publication date: July 12, 2018
Applicants: Board of Regents of the University of Texas System, Amprion, Inc.
Inventors: Claudio Soto-Jara, Russell M. Lebovitz, Benedikt K. Vollrath, Mohammad Shahnawaz
Detection of misfolded amyloid beta protein
Patent number: 9910049
Abstract: Methods and kits are provided for amplifying and detecting A? proteins from samples, for example, from patients having Alzheimer's Disease. For example, a method for determining a presence of a soluble, misfolded A? protein may include contacting the sample with a monomeric, folded A? protein to form an incubation mixture; conducting an incubation cycle two or more times on the incubation mixture effective to form an amplified portion of misfolded A? protein; incubating the incubation mixture effective to cause misfolding and/or aggregation of at least a portion of the monomeric, folded A? protein; physically disrupting the incubation mixture effective to at least partly de-aggregate at least a portion of a misfolded A? aggregate present; and determining the presence of the soluble, misfolded A? protein in the sample by detecting at least a portion of the amplified portion of misfolded A? protein.

Type: Grant
Filed: September 11, 2015
Date of Patent: March 6, 2018
Assignees: AMPRION, INC., THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM
Inventors: Claudio Soto Jara, Mohammad Shahnawaz, Russell M. Lebovitz, Benedikt K. Vollrath

https://patents.justia.com/assignee/amprion-inc

_______________________

Exosomes help track effectiveness of experimental Parkinson's disease drug

March 21, 2019

..
...
...
This study confirms the value of exosomes as an additional analytical tool to show target engagement in clinical trials. The investigators are optimistic about future work to examine how exosomes could help speed up validation in clinical trials of potential new drugs for PD, Alzheimerâ??s disease, and other neurological disorders.

https://www.nia.nih.gov/news/exosomes-help-track-effectiveness-experimental-parkinsons-disease-drug

___________________

NIA Small Business funding seeks to find blood-based diagnostic for Alzheimerâ??s disease

July 30, 2019

A test for early detection of Parkinsonâ??s disease, which recently received Breakthrough Device Designation by the FDA, may have the potential to become an early measure for Alzheimerâ??s disease as well. With NIH funding that includes Small Business grants from NIA, Amprion, a California-based biotech company, has developed a technology to detect very small amounts of proteins in the cerebrospinal fluid and bloodstream that could be used to detect the diseases.

Having an effective, accurate, and easy-to-administer test for diagnosing Alzheimerâ??s and Parkinsonâ??s diseases is crucial to help develop treatments and potentially find cures for these diseases. Currently, the use of biomarkers for Alzheimerâ??s disease in a clinical setting, such as a doctorâ??s office, is limited.

The FDAâ??s Breakthrough Devices Program is designed to speed up development, assessment, and review of medical devices that could provide more effective treatment or diagnosis of life-threatening or irreversibly debilitating diseases or conditions. The FDA designation puts Amprionâ??s Protein Misfolding Cyclic Amplification (PMCA) system a step closer to approval for early detection of the alpha-synuclein protein, which would help diagnose Parkinsonâ??s disease. Amprion anticipates market rollout within 18 months. Ongoing efforts funded by NIA grants are dedicated to similarly detecting proteins associated with Alzheimerâ??s disease.

The ongoing NIA funding is specific to detecting traces of amyloid and tau aggregates. Amprion hypothesizes that detection of misfolded amyloid and tau oligomers circulating in cerebrospinal fluid and blood may be the basis for an early Alzheimerâ??s biomarker. With the funding, the company plans to adapt the PMCA technology for specific and highly sensitive detection in human cerebrospinal fluid and blood plasma, perform studies of specificity and sensitivity using a large number of samples from people with Alzheimerâ??s, and evaluate the utility of PMCA for monitoring Alzheimerâ??s disease progression.

The PMCA technology has been under development, with the support of several NIH grants from NIA, the National Institute of Neurological Disorders and Stroke, and the National Institute of Allergy and Infectious Diseases, for the past 15 years. PMCA, also known as RT-QuIC, is a platform technology to detect misfolded protein oligomers implicated in various neurodegenerative diseases, including Alzheimer's, Parkinson's, and prion diseases. The technique harnesses the way proteins misfold, aggregate, and spread in the brain and then amplifies their quantity so small amounts can be found in biological fluids. The PMCA/RT-QuIC assay to detect misfolded prion protein is already being used to diagnose prion diseases. Amprion was founded, with funding from several Small Business Innovation Research (SBIR)/Small Business Technology Transfer (STTR) grants, to facilitate the commercialization of these assays.

This research is funded in part by NIA grants R42AG049562 and R42AG058333.

https://www.nia.nih.gov/news/nia-small-business-funding-seeks-find-blood-based-diagnostic-alzheimers-disease

______________

Flipped PS travels the bloodstream and breaks the blood brain barrier ....looks like Independent BOD Catherine Mackey will be confronted with questions